文献速递老年慢病共病管理安宁疗护多重用药

VA养老院临终期退伍军人糖尿病药物降阶梯治疗现状

Deintensification of Diabetes Medications among Veterans at the End of Life in VA Nursing Homes.
PubMed 文献 · J Am Geriatr Soc · 2020-02-17

该回顾性队列研究纳入2009至2015财年入住VA社区生活中心的6960名预期寿命有限和/或晚期痴呆的糖尿病退伍军人,其中超过40%存在潜在过度治疗。90天降阶梯治疗累积发生率为45.5%,较低HbA1c和使用低血糖高风险药物与降阶梯可能性更高相关。

要点

  • 预期寿命有限和/或晚期痴呆的糖尿病退伍军人中超过40%存在潜在过度治疗。
  • 90天降阶梯治疗累积发生率为45.5%,不足半数潜在过度治疗者接受了降阶梯。
  • 较低HbA1c和使用低血糖高风险药物与降阶梯可能性更高相关。

核心结论

  • 潜在过度治疗的退伍军人中不足半数发生了降阶梯治疗。
  • 降阶梯治疗与较低HbA1c值及使用低血糖高风险药物相关性更强,而非其他居民特征。

研究设计与样本

  • 回顾性队列研究,使用VA与Medicare临床/管理数据及Minimum Data Set评估 linked 数据。
  • 纳入2009至2015财年入住VA社区生活中心、入院90天内测量HbA1c的6960名糖尿病退伍军人,均存在预期寿命有限和/或晚期痴呆。

主要发现

  • 超过40%(n=3056)的糖尿病社区生活中心居民存在潜在过度治疗。
  • 90天降阶梯治疗累积发生率为45.5%。

关键数值与推荐

  • 潜在过度治疗定义为HbA1c≤7.5%且正在接受降糖药物治疗。
  • 降阶梯治疗定义为连续7天停药或减量。

临床怎么用

  • 对预期寿命有限和/或晚期痴呆的糖尿病退伍军人,应评估是否存在潜在过度治疗并考虑降阶梯。
  • 低HbA1c和使用低血糖高风险药物(如磺脲类)的患者可能是降阶梯的重点对象。
  • 临终状态可促进降阶梯决策,但家庭/辅助生活机构入院、肥胖和外周血管疾病可能降低降阶梯可能性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Many older adults with limited life expectancy and/or advanced dementia (LLE/AD) are potentially overtreated for diabetes and may benefit from deintensification. Our aim was to examine the incidence and predictors of diabetes medication deintensification in older Veterans with LLE/AD who were potentially overtreated at admission to Veterans Affairs (VA) nursing homes (community living centers [CLCs]). DESIGN: Retrospective cohort study using linked VA and Medicare clinical/administrative data and Minimum Data Set assessments. SETTING: VA CLCs. PARTICIPANTS: A total of 6960 Veterans with diabetes and LLE/AD admitted to VA CLCs in fiscal years 2009 to 2015 with hemoglobin (Hb)A1c measured within 90 days of admission. MEASUREMENTS: We evaluated treatment deintensification (discontinuation or dose reduction for a consecutive 7-day period) among residents who were potentially overtreated (HbA1c ≤7.5% and receiving hypoglycemic medications). Competing risk models assessed 90-day cumulative incidence of deintensification. RESULTS: More than 40% (n = 3056) of Veteran CLC residents with diabetes were potentially overtreated. The cumulative incidence of deintensification at 90 days was 45.5%. Higher baseline HbA1c values were associated with a lower likelihood of deintensification (e.g., HbA1c 7.0-7.5% vs <6.0%; adjusted risk ratio [aRR] = .57; 95% confidence interval [CI] = .50-.66). Compared with non-sulfonylurea oral agents (e.g., metformin), other treatment regimens were more likely to be deintensified (aRR = 1.31-1.88), except for basal insulin (aRR = .59; 95% CI = .52-.66). The only resident factor associated with increased likelihood of deintensification was documented end-of-life status (aRR = 1.12; 95% CI = 1.01-1.25). Admission from home/assisted living (aRR = .85; 95% CI = .75-.96), obesity (aRR = .88; 95% CI = .78-.99), and peripheral vascular disease (aRR = .90; 95% CI = .81-.99) were associated with decreased likelihood of deintensification. CONCLUSION: Deintensification of treatment regimens occurred in less than one-half of potentially overtreated Veterans and was more strongly associated with low HbA1c values and use of medications with high risk for hypoglycemia, rather than other resident characteristics. J Am Geriatr Soc 68:736-745, 2020.

来源:J Am Geriatr Soc,查看原文。版权归原作者所有。

引用

  1. Niznik JD, Hunnicutt JN, Zhao X, et al. Deintensification of Diabetes Medications among Veterans at the End of Life in VA Nursing Homes. J Am Geriatr Soc. 2020. PMID: 32065387. doi:10.1111/jgs.16360

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。